ARTICLE | Clinical News

Rilutek glutamate antagonist data

April 10, 1995 7:00 AM UTC

RPR (New York) announced that the drug shows an impact on survival in a preliminary analysis of a Phase III trial in more than 950 patients.

A clear, statistically significant survival benefit in both bulbar- and limb-onset forms of the disease is apparent from the analysis so far, the company told BioCentury. "We've generally confirmed the Phase II finding" of a three-month increase in survival, spokesperson Bob Pearson said. ...